Cardiovascular Disease Doctors in Point Pleasant, WV - Medicare Status, Address, Contact

1 Cardiovascular Disease doctors found. Showing 1 - 1

Timothy A Damron, MD
Internal Medicine - Cardiovascular Disease
Medicare: Accepting Medicare Assignments
Practice Location: 2520 Valley Drive, Point Pleasant, WV 25550
Phone: 304-675-1484 Fax: 304-675-1496

News Archive

Senate Dems express increasing alarm over website issues

With its first rocky month down, some say the most critical days are beginning for healthcare.gov. Meanwhile, the technical difficulties that have plagued the site are starting to chip away at the Democratic unity that has, so far, surrounded it. Some senators, for instance, are beginning to express concerns about its impact on the upcoming mid-term election and are calling for a delay in the individual mandate penalties if the website is not soon operational.

Opinion pieces, blog react to new public-private NTD initiative

Pharmaceutical company heads and global health leaders gathered at a conference on Monday in London to announce the formation of a large public-private partnership to fight neglected tropical diseases (NTDs) and endorse the "London Declaration on Neglected Tropical Diseases", in which they pledged to work together and track progress.

Precision epigenome editing can repair genetic syndrome of intellectual disability

Using a targeted gene epigenome editing approach in the developing mouse brain, Johns Hopkins Medicine researchers reversed one gene mutation that leads to the genetic disorder WAGR syndrome, which causes intellectual disability and obesity in people.

Eisai's Dacogen five-day dosing regimen for treatment of MDS receives FDA approval

Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen® (decitabine) for Injection to treat patients with myelodysplastic syndromes (MDS), a group of bone marrow diseases that alter the production of functional blood cells.

FDA approves Mylan Pharmaceuticals' generic NuLytely laxative

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Polyethylene Glycol 3350, Sodium Chloride, Sodium Bicarbonate and Potassium Chloride for Oral Solution (with Flavor Packs), the generic version of Braintree Laboratories' NuLytely® laxative.

Cardiovascular Disease Doctors in Point Pleasant, WV Accepting Medicare